All In Biotech

Drug Trial Radar · NCT05087134

Characterizing LAM With 11C-Choline PET/CT

Characterizing Lymphangioleiomyomatosis (LAM) With 11C-Choline PET/CT

Last checked: Nov 20, 2026Latest source record: Oct 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 2021

Primary completion

Sep 2022

Study completion Sep 2023

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It was reported that TSC2-deficient cells enhance phosphatidylcholine synthesis via the Kennedy pathway. 11C-Choline can reflect the metabolic process of choline in vivo by intravenous injection. The purpose of this study is the ability of 11C-Choline PET/CT to evaluate the baseline condition of LAM patients and the efficacy of rapamycin after treatment.

Conditions

  • Lymphangioleiomyomatosis

Interventions

  • 11C-CholineDrug

    11C-Choline were injected into the patients before the PET/CT scans

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Standardized uptake value of 11C-Choline in LAM lesionsTime frame: through study completion, an average of 2 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking union medical college hospital

    Beijing, Dongcheng, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.